Opus Genetics revises Cohort 1 data presentation
The company corrected a logMAR-to-ETDRS translation error in its data presentation and said low-dose Cohort 1 showed functional and structural gains with no serious adverse events.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.